6,611 results match your criteria ctdna circulating

Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA.

Tae-Kyung Yoo

Adv Exp Med Biol 2021 ;1187:337-361

Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Cancer is associated with gene mutations, and the analysis of tumor-associated mutations is increasingly used for diagnostic, prognostic, and treatment purposes. These molecular landscapes of solid tumors are currently obtained from surgical or biopsy specimens. However, during cancer progression and treatment, selective pressures lead to additional genetic changes as tumors acquire drug resistance. Read More

View Article and Full-Text PDF
January 2021

Next-Generation Sequencing-Based Biomarkers in Breast Cancer.

Adv Exp Med Biol 2021 ;1187:323-335

Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.

For the realization of precision medicine in cancer treatment, discovery, and validation of clinically useful biomarker is the most important prerequisite. Biomarkers are needed and used for evaluation of cancer susceptibility, cancer screening (early detection), cancer subtyping, prediction of prognosis, decision of appropriate adjuvant therapy and duration of therapy, and for monitoring of recurrence. Biomarkers are also needed for decision of target therapy in metastatic cancer and monitoring of their response during follow-up. Read More

View Article and Full-Text PDF
January 2021

Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics.

Adv Exp Med Biol 2021 ;1187:215-244

Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, South Korea.

Intra- and Inter-tumoral heterogeneity is one of the main hurdles in diagnosing and treating breast cancer. Selecting, sampling, and sequencing the samples appropriately provide unique opportunities in realizing precision medicine. This chapter reviews some of the past landmarks, state-of-the-art technologies, and future directions of translational research in terms of tumor sampling technologies and sequencing in breast cancer. Read More

View Article and Full-Text PDF
January 2021

The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.

Cancer Med 2021 May 12. Epub 2021 May 12.

Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Background: EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic value has not been clarified.

Methods: Patients with NSCLC who progressed after treatment with EGFR-TKI, and with EGFR T790 M detected by an approved companion diagnostic test (cobas ), were treated with osimertinib. Plasma samples were collected before and after treatment. Read More

View Article and Full-Text PDF

[Research progress of serum biomarkers for early screening of hepatocellular carcinoma].

W Zhu Y Huang

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):308-312

Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha 410008, China.

The latest research data shows that the cause of death of liver cancer patients ranks third among malignant tumors. The global situation of early detection, early diagnosis and early treatment of liver cancer is severe. Therefore, how to achieve early diagnosis of liver cancer has important clinical significance. Read More

View Article and Full-Text PDF

Combining Serum DNA Methylation Biomarkers and Protein Tumor Markers Improved Clinical Sensitivity for Early Detection of Colorectal Cancer.

Int J Genomics 2021 21;2021:6613987. Epub 2021 Apr 21.

Department of Clinical Laboratory, Nanjing Integrated Traditional Chinese and Western Medicine Hospital, Nanjing, Jiangsu 210014, China.

Background: Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide and in China. Early CRC screening is the best approach to reduce its incidence and mortality rates. The ColoDefense test, a multiplex qPCR assay simultaneously detecting both methylated and genes, has demonstrated improved clinical performance on either methylation biomarker alone for CRC screening with both blood and stool samples. Read More

View Article and Full-Text PDF

Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors.

Sci Rep 2021 May 11;11(1):9984. Epub 2021 May 11.

Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA.

Among non-small cell lung cancer (NSCLC) patients with therapeutically targetable tumor mutations in epidermal growth factor receptor (EGFR), not all patients respond to targeted therapy. Combining circulating-tumor DNA (ctDNA), clinical variables, and radiomic phenotypes may improve prediction of EGFR-targeted therapy outcomes for NSCLC. This single-center retrospective study included 40 EGFR-mutant advanced NSCLC patients treated with EGFR-targeted therapy. Read More

View Article and Full-Text PDF

Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.

Eur Urol Oncol 2021 May 8. Epub 2021 May 8.

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Context: Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited.

Objective: To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitoring, and prognostication of bladder and kidney cancer. Read More

View Article and Full-Text PDF

Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.

Mol Diagn Ther 2021 May 10. Epub 2021 May 10.

James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.

Background: Circulating tumor DNA (ctDNA) may complement radiography for interim assessment of patients with cancer.

Objective: Our objective was to explore the relationship between changes in plasma ctDNA versus radiographic imaging among patients with metastatic melanoma.

Methods: Using the Idylla system, we measured B-Raf proto-oncogene (BRAF) V600 ctDNA in plasma from 15 patients with BRAF V600E/K-positive primary tumors undergoing standard-of-care monitoring, including cross-sectional computed tomography (CT) imaging. Read More

View Article and Full-Text PDF

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Mol Oncol 2021 May 10. Epub 2021 May 10.

Germans Trias i Pujol Research Institute and Hospital, Badalona, Spain.

Over the past decade, substantial developments have been made in the detection of circulating tumor DNA (ctDNA) - cell-free DNA (cfDNA) fragments released into the circulation from tumor cells and displaying the genetic alterations of those cells. As such, ctDNA detected in liquid biopsies serves as a powerful tool for cancer patient stratification, therapy guidance, detection of resistance and relapse monitoring. In this Review, we describe lung cancer diagnosis and monitoring strategies using ctDNA detection technologies and compile recent evidence regarding lung-cancer-related mutation detection in liquid biopsy. Read More

View Article and Full-Text PDF

Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low-Dose Computed Tomography.

Front Oncol 2021 21;11:555331. Epub 2021 Apr 21.

The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, QLD, Australia.

Lung cancer is currently the leading cause of cancer death in both developing and developed countries. Given that lung cancer has poor prognosis in later stages, it is essential to achieve an early diagnosis to maximize patients' overall survival. Non-small cell lung cancer (NSCLC) is the most common form of primary lung cancer in both smokers and non-smokers. Read More

View Article and Full-Text PDF

Extracellular vesicles in prostate cancer: a narrative review.

Transl Androl Urol 2021 Apr;10(4):1890-1907

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Over the past decade, there has been remarkable progress in prostate cancer biomarker discovery using urine- and blood-based assays. A liquid biopsy is a minimally invasive procedure to investigate the cancer-related molecules in circulating tumor cells (CTCs), cell-free DNA, and extracellular vesicles (EVs). Liquid biopsies have the advantage of detecting heterogeneity as well as acquired resistance in cancer. Read More

View Article and Full-Text PDF

Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?

Cancer Treat Res Commun 2021 Apr 25;28:100380. Epub 2021 Apr 25.

Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium. Electronic address:

Multiple myeloma (MM), is a heterogeneous disease in which chromosomal abnormalities are important for prognostic risk stratification. Cytogenetic profiling with FISH on plasma cells from bone marrow samples (BM-PCs) is the current gold standard, but variable infiltration of plasma cells or failed aspiration can hamper this process. Ultra-low coverage sequencing (ULCS) of circulating cell-free DNA (ccfDNA) may offer a minimally invasive alternative for the work-up of these cases. Read More

View Article and Full-Text PDF

Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.

Int J Cancer 2021 May 7. Epub 2021 May 7.

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Detection of tumour-specific circulating cell-free DNA in plasma (ctDNA) fails in a significant number of cases depending on the clinical context. The primary aim was to investigate clinicopathological factors associated with detection of ctDNA in patients with RAS-/BRAF-mutated metastatic colorectal cancer (mCRC) prior to first-line therapy. A secondary aim was to evaluate the prognostic impact of ctDNA compared to other biomarkers. Read More

View Article and Full-Text PDF

Liquid biopsies to distinguish malignant from benign pulmonary nodules.

Thorac Cancer 2021 May 7. Epub 2021 May 7.

Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Anhui Medical University, Hefei, China.

Over the past decades, low-dose computed tomography (LD-CT) screening has been widely used for the early detection of lung cancer. Increasing numbers of indeterminate pulmonary nodules are now being discovered. However, it remains challenging to distinguish malignant from benign pulmonary nodules, especially those considered to be small or ground-glass (GGN) nodules. Read More

View Article and Full-Text PDF

Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies.

Monaldi Arch Chest Dis 2021 May 4. Epub 2021 May 4.

Division of Molecular Genetics and Cancer, Nitte University Centre For Science Education and Research (NUCSER), Nitte (Deemed to be University), Mangalore .

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effectively used in treatment of non-small cell lung cancer (NSCLC). Mutation profile of tyrosine kinase domain of EGFR determines the eligibility of the patients for tyrosine kinase inhibitor (TKI) therapy. Liquid biopsy, which relies on circulating tumor-derived nucleic acids, has emerged as an effective tool in lung cancer management with proven diagnostic, prognostic and predictive applications. Read More

View Article and Full-Text PDF

TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer.

PeerJ 2021 16;9:e11146. Epub 2021 Apr 16.

Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), Shanghai, China.

Background: Gastric cancer (GC) is a heterogeneous disease that encompasses various molecular subtypes. The molecular mutation characteristics of circulating tumor DNA (ctDNA) in advanced gastric cancer (AGC), especially the clinical utility of TP53 mutation and MET amplification in ctDNA need to be further explored.

Objectives: The aim of this study was mainly to assess the clinical utility of TP53 mutation and MET amplification in ctDNA as biomarkers for monitoring disease progression of AGC. Read More

View Article and Full-Text PDF

Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.

Clin Epigenetics 2021 May 5;13(1):104. Epub 2021 May 5.

Departments of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.

Background: Definitive diagnosis of primary central nervous system lymphoma (PCNSL) requires invasive surgical brain biopsy, causing treatment delays. In this paper, we identified and validated tumor-specific markers that can distinguish PCNSL from other CNS tumors in tissues. In a pilot study, we tested these newly identified markers in plasma. Read More

View Article and Full-Text PDF

A homogeneous digital biosensor for circulating tumor DNA by the enumeration of a dual-color quantum dot complex.

Analyst 2021 May;146(9):3034-3040

School of Chemistry and Materials Science, Jiangsu Normal University, Shanghai Road 101, Xuzhou, Jiangsu, China.

Monitoring ctDNA in blood is important for cancer management. Here, a one-step single particle counting approach was developed for directly quantifying ctDNA in plasma. Hairpin DNA containing a triple helix stem was immobilized onto QD 585 as a probe. Read More

View Article and Full-Text PDF

Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.

Am J Cancer Res 2021 15;11(4):1709-1718. Epub 2021 Apr 15.

Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.

Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC), frequent despite the availability of multiple treatment modalities, may be partly explained by the presence of immunosuppressive cell populations. We hypothesized that progression of disease could be prevented by the administration of an activated T cell immunotherapy (ACT) at time points when immunosuppressive populations increased in peripheral blood. In an N-of-1 study, a patient with multiple primary bladder high grade urothelial carcinomas, previously treated with standard local resection and chemotherapy but with evidence of progression, received ACT consisting of dendritic cells mixed with cytokine induced killer cells (DC/CIK), intravenously 18 times over a 6 year period at indicated time of observed increases in peripheral blood immunosuppressive CD8/CD28 cells. Read More

View Article and Full-Text PDF

The Landscape of Cell-free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.

Clin Cancer Res 2021 May 4. Epub 2021 May 4.

Berry Oncology Corporation, Beijing, China.

Purpose: Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful non-invasive biomarker for cancer. However, the HBV integration and mutation landscape on cfDNA remains unclear. Read More

View Article and Full-Text PDF

Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology.

Cancers (Basel) 2021 Apr 29;13(9). Epub 2021 Apr 29.

Program in Solid Tumors, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.

Among the different components that can be analyzed in liquid biopsy, the utility of exosomes is particularly promising because of their presence in all biological fluids and their potential for multicomponent analyses. Exosomes are extracellular vesicles with an average size of ~100 nm in diameter with an endosomal origin. All eukaryotic cells release exosomes as part of their active physiology. Read More

View Article and Full-Text PDF

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook.

Evi Lianidou

Mol Oncol 2021 May 3. Epub 2021 May 3.

Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, University of Athens, 15771, Athens, Greece.

Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real-time follow up of cancer and overcomes many limitations of tissue biopsies. Epigenetic alterations have a high potential to provide a valuable source of innovative biomarkers for cancer, owing to their stability, frequency and non-invasive accessibility in bodily fluids. Numerous DNA methylation markers are now tested in circulating tumor DNA (ctDNA) as potential biomarkers, in various types of cancer. Read More

View Article and Full-Text PDF

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.

Nat Med 2021 May 3. Epub 2021 May 3.

CRUK Manchester Institute Cancer Biomarker Centre, Manchester, UK.

Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC). AUC is characterized by several recurrent targetable genomic alterations. This study ( NCT02546661 , BISCAY) combined durvalumab with relevant targeted therapies in biomarker-selected chemotherapy-refractory AUC populations including: (1) fibroblast growth factor receptor (FGFR) inhibitors in tumors with FGFR DNA alterations (FGFRm); (2) pharmacological inhibitor of the enzyme poly-ADP ribose polymerase (PARP) in tumors with and without DNA homologous recombination repair deficiency (HRRm); and (3) TORC1/2 inhibitors in tumors with DNA alteration to the mTOR/PI3K pathway. Read More

View Article and Full-Text PDF

Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.

PLoS Med 2021 May 3;18(5):e1003620. Epub 2021 May 3.

The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

Background: In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker of minimal residual disease, is a powerful prognostic factor in patients with nonmetastatic colorectal cancer (CRC). Serial analysis of ctDNA in patients with resectable CRLM could inform the optimal use of perioperative chemotherapy. Read More

View Article and Full-Text PDF

The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer.

Front Oncol 2021 16;11:634316. Epub 2021 Apr 16.

Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal.

Liquid biopsy is an emerging technology with a potential role in the screening and early detection of lung cancer. Several liquid biopsy-derived biomarkers have been identified and are currently under ongoing investigation. In this article, we review the available data on the use of circulating biomarkers for the early detection of lung cancer, focusing on the circulating tumor cells, circulating cell-free DNA, circulating micro-RNAs, tumor-derived exosomes, and tumor-educated platelets, providing an overview of future potential applicability in the clinical practice. Read More

View Article and Full-Text PDF

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

J Oncol 2021 12;2021:6627241. Epub 2021 Apr 12.

Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China.

In recent years, the studies on ovarian cancer have made great progress, but the morbidity and mortality of patients with ovarian cancer are still very high. Due to the lack of effective early screening and detecting tools, 70% of ovarian cancer patients are diagnosed at an advanced stage. The overall survival rate of ovarian cancer patients treated with surgical combined with chemotherapy has not been significantly improved, and they usually relapse or resist chemotherapy. Read More

View Article and Full-Text PDF

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System.

Front Pharmacol 2021 14;12:657743. Epub 2021 Apr 14.

Laboratory of Clinical and Experimental Pathology, Biobank BB-0033-00025, Centre Hospitalier Universitaire Nice, Nice, France.

The introduction of liquid biopsies for the detection of mutations in non-small cell lung cancer patients (NSCLC) has revolutionized the clinical care. However, liquid biopsies are technically challenging and require specifically trained personnel. To facilitate the implementation of liquid biopsies for the detection of mutations from plasma, we have assessed a fully automated cartridge-based qPCR test that allows the automatic detection of mutations directly from plasma. Read More

View Article and Full-Text PDF

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.

Mol Oncol 2021 May 2. Epub 2021 May 2.

Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.

Circulating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial liquid biopsies to enable tumor genome analysis throughout the course of treatment. We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib-treated metastatic colorectal cancer (mCRC) patients. We analyzed longitudinally collected plasma cfDNA of 43 mCRC patients prospectively enrolled in the phase II TEXCAN trial by IntPlex qPCR. Read More

View Article and Full-Text PDF

Nanotechnology in emerging liquid biopsy applications.

Nano Converg 2021 May 2;8(1):13. Epub 2021 May 2.

Department of Chemistry, University of Patras, Rio, 26504, Patras, Greece.

Liquid biopsy is considered as the most attractive alternative to traditional tissue biopsies. The major advantages of this approach lie in the non-invasive procedure, the rapidness of sample collection and the potential for early cancer diagnosis and real-time monitoring of the disease and the treatment response. Nanotechnology has dynamically emerged in a wide range of applications in the field of liquid biopsy. Read More

View Article and Full-Text PDF